PMN310 has been granted Fast Track Designation by the U.S. FDA for the treatment of Alzheimer’s disease.

View Press Release

Posters & Publications

Years of Research at Your Fingertips

ProMIS Neurosciences’ publications and posters provide ample background on our research surrounding neurodegenerative diseases.

Filter By:

EpiSelect™ Platform

Prediction of Misfolding-Speci c Epitopes in SOD1 Using Collective Coordinates

View EpiSelect™ Platform
PMN267 | TDP-43

Rational Generation of Monoclonal Antibodies and Intrabodies Selective for Pathogenic TDP-43

View PMN267 | TDP-43
PMN311 | AD Vaccine

Alzheimer's Disease Vaccine Presentation

View PMN311 | AD Vaccine
PMN311 | AD Vaccine

Narration of Alzheimer's Disease Vaccine Presentation

View PMN311 | AD Vaccine
PMN440 | A-Syn Vaccine

Alpha-synuclein Vaccine Presentation

View PMN440 | A-Syn Vaccine
PMN440 | A-Syn Vaccine

Narration of Alpha-synuclein Vaccine Presentation

View PMN440 | A-Syn Vaccine
PMN310 | Amyloid-Beta

Phase 1a Single Ascending Dose Study of PMN310, a monoclonal antibody directed against toxic Aβ oligomers

View PMN310 | Amyloid-Beta
PMN310 | Amyloid-Beta

Distinguishing between Ab-directed antibodies: Ability of PMN310 to target toxic oligomers despite competing species

View PMN310 | Amyloid-Beta
PMN311 | AD Vaccine

Novel approach to optimization of Alzheimer’s vaccine configuration for maximal targeting of toxic amyloid-beta oligomers

View PMN311 | AD Vaccine
PMN310 | Amyloid-Beta

Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies

View PMN310 | Amyloid-Beta
Discovery

Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration

View Discovery
PMN310 | Amyloid-Beta

Selective targeting and protection against toxic amyloid-beta oligomers by PMN310, a monoclonal antibody rationally designed for greater therapeutic potency in Alzheimer’s disease

View PMN310 | Amyloid-Beta